ArticleDiabetology & metabolic syndrome2025
Effects of dapagliflozin on podocyte damage and oxidative stress in patients with diabetic nephropathy.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dapagliflozin attenuates methotrexate-induced hepatorenal toxicity in rats: insights into oxidative stress, inflammation, autophagy and apoptosis.Molecular and cellular biochemistry · 2026Article
- Dynamics and Predictive Values of Urinary Podocyte Biomarkers Following SGLT2 Inhibition in CKD.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study explores the effect of dapagliflozin treatment on podocyte injury and oxidative stress in patients with early diabetic nephropathy (T2DN). Methods: Clinical data from 78 patients with early T2DN, admitted to our hospital between June 2021 and June 2023, were collected and analyzed.
methodsThis study was a single-center, prospective randomized controlled trial. Clinical data from 78 patients with early T2DN admitted to our hospital between June 2021 and June 2023 were collected and analyzed. The 78 patients were divided into two groups: observation and control, with 39 receiving different treatments. Patients in the control group received sitagliptin phosphate tablets, while patients in the observation group received dapagliflozin tablets. The total efficacy of therapy and the frequency of adverse reactions were compared between the observation and control groups. Serum concentrations of malondialdehyde (MDA), reactive oxygen species (ROS), superoxide dismutase (SOD), podocyte marker protein (PCX), podocyte slit diaphragm protein (Nephrin), gelatinase-associated apolipoprotein (NGAI), fasting blood glucose (FBG), and glycated hemoglobin (HbA1c) were analyzed in both groups.
resultsThe total effective rate of treatment in the observation group was significantly higher than in the control group (89.74% vs. 66.67%, P < 0.05). Both groups showed significant decreases in serum MDA and ROS levels and increases in SOD levels after treatment (P < 0.05). However, the observation group exhibited a greater reduction in oxidative stress markers compared to the control group (P < 0.05). Podocyte damage indicators (PCX and Nephrin) increased significantly in both groups, while NGAI levels decreased after treatment. The observation group demonstrated more significant improvements in podocyte markers compared to the control group (P < 0.05). FBG and HbA1c levels decreased significantly in both groups after treatment, with the observation group showing a more substantial reduction (P < 0.05). The incidence of adverse reactions was higher in the observation group (23.08%) compared to the control group (10.26%), but this difference was not statistically significant (P > 0.05).
conclusionDapagliflozin has a good safety profile, demonstrating superior efficacy in reducing oxidative stress and podocyte injury in patients with early-stage T2DN. It can effectively lower blood glucose and has promising clinical applications in managing diabetic nephropathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.